Performance evaluation of the Ortho VITROS SARS-CoV-2 Spike-Specific Quantitative IgG test by comparison with the surrogate virus neutralizing antibody test and clinical assessment

PLoS One. 2023 Jan 24;18(1):e0279779. doi: 10.1371/journal.pone.0279779. eCollection 2023.

Abstract

Background: Despite the worldwide campaigns of COVID-19 vaccinations, the pandemic is still a major medical and social problem. The Ortho VITROS SARS-CoV-2 spike-specific quantitative IgG (VITROS S-IgG) assay has been developed to assess neutralizing antibody (NT antibody) against SARS-CoV-2 spike (S) antibodies. However, it has not been evaluated in Japan, where the total cases and death toll are lower than the rest of the world.

Methods: The clinical performance of VITROS S-IgG was evaluated by comparing with the NT antibody levels measured by the surrogate virus neutralizing antibody test (sVNT). A total of 332 serum samples from 188 individuals were used. Of these, 219 samples were from 75 COVID-19 patients: 96 samples from 20 severe/critical cases (Group S), and 123 samples from 55 mild/moderate cases (Group M). The remaining 113 samples were from 113 healthcare workers who had received 2 doses of the BNT162b2 vaccine.

Results: VITROS S-IgG showed good correlation with the cPass sVNT assay (Spearman rho = 0.91). Both VITROS S-IgG and cPass sVNT showed significantly higher plateau levels of antibodies in Group S compared to Group M. Regarding the humoral immune responses after BNT162b2 vaccination, individuals who were negative for SARS-CoV-2 nucleocapsid (N)-specific antibodies had statistically lower titers of both S-IgG and sVNT compared to individuals with a history of COVID-19 and individuals who were positive for N-specific antibodies without history of COVID-19. In individuals who were positive for N-specific antibodies, S-IgG and sVNT titers were similar to individuals with a history of COVID-19.

Conclusions: Although the automated quantitative immunoassay VITROS S-IgG showed a reasonable correlation with sVNT antibodies, there is some discrepancy between Vitros S-IgG and cPass sVNT in milder cases. Thus, VITROS S-IgG can be a useful diagnostic tool in assessing the immune responses to vaccination and herd immunity. However, careful analysis is necessary to interpret the results.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Blocking
  • Antibodies, Neutralizing
  • Antibodies, Viral
  • BNT162 Vaccine
  • Blood Group Antigens*
  • COVID-19 Testing
  • COVID-19*
  • Humans
  • Immunoglobulin G
  • SARS-CoV-2

Substances

  • BNT162 Vaccine
  • Antibodies, Blocking
  • Antibodies, Viral
  • Immunoglobulin G
  • Antibodies, Neutralizing
  • Blood Group Antigens

Grants and funding

This work was supported in part by Japan Agency for Medical Research and Development (grant No. JP20fk0108472) to Toshio Naito and by Japan Society for the Promotion of Science Grants-in Aid for Scientific Research (grant No. 22K15675) to Dr. Satomi Takei. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.